

## Oncology Areas of Interest

(Investigator Initiated Studies and Research Collaborations)

### R2810 (Cemiplimab\_Libtayo)

#### *Cutaneous Squamous Cell Carcinoma (CSCC)*

- *Neoadjuvant settings combination studies*
- *Adjuvant use of cemiplimab in select populations*
- *Combination studies with cemiplimab in advanced stages*
- *Use of cemiplimab in population already treated for metastatic disease with immuno-therapy*

#### *Basal Cell Carcinoma (BCC)*

- *Combination studies with cemiplimab in all treatment stages*
- *Cemiplimab in surgery or RT eligible patients before other systemic therapies*
- *Cemiplimab in other pre-BCC genetic syndromes or high-risk populations*
- *Insights on the biology of disease, genetic risk for progression, biomarkers*

#### *Other Skin Cancers*

- *Study proposals for skin tumor types (Merkel Cell, Melanoma, Adnexal Tumors, Skin Lymphomas) will be considered and will be evaluated under provision of strong scientific rationale and solid hypothesis of benefit/safety increment over the current treatment landscape*

#### *Metastatic Non-Small Cell Lung Cancer (mNSCLC)*

- *Studies in select patient subgroup to address specific medical needs not covered by the current standard of care.*
- *Studies that can further improve understanding of the disease and inform future directions of specific treatments*

#### *Other Cancers*

- *Study proposals for other cancers will be considered and will be evaluated under provision of strong scientific rationale and solid hypothesis of benefit/safety increment over the current treatment landscape:*
  - *Evaluation of cemiplimab in rare and hard-to-treat populations and in novel combinations/modalities*
  - *Combination of cemiplimab with agents that address complementary mechanisms of action*

(v2.0, 28Sep2022)

## Oncology Areas of Interest

(Investigator Initiated Studies and Research Collaborations)

### REGN3767 (anti-LAG3)\_fianlimab

*Studies to support further understanding of role of Fianlimab & Cemiplimab in melanoma including:*

- *Novel combinations/modalities*
- *High risk populations with unmet need including pediatrics*
- *IO-refractory patients*

*Studies with strong scientific rationale expected to increase understanding of LAG3 biology in preclinical mouse models and in vitro studies, and translational biomarker studies, to inform combination therapy of fianlimab + cemiplimab in melanoma*

**Note that Regeneron is not currently accepting proposals for Investigator Sponsored Studies or Research Collaborations using fianlimab in the European Union.**

(v1.1, 20Mar2023)

### CMP-001 (TLR9)\_vidutolimod

- *Studies to support further understanding of the role of vidutolimod (+/- cemiplimab) in indications that are amenable to intralesional administration*
  - *Clinical interventional proposals in indications of CSCC, BCC, MCC and melanoma will not be considered, however clinical translational studies with strong research component are of interest*
- *Studies with strong rationale expected to increase understanding of vidutolimod biology in preclinical mouse models and in vitro studies, and translational biomarker studies*

**Note that Regeneron is not currently accepting proposals for Investigator Sponsored Studies or Research Collaborations using vidutolimod in the European Union.**

(v1.0, 2Mar2023)